Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-BCMA CAR-T cells
for the treatment of multiple myeloma
A non randomized study ,plans to enrollment 24 patients of B cell lymphoma divided into low,
medium and high dose groupsto evaluate the safety and tolerability of CD19-BCMA CAR - T
cells immunotherapy in patients with relapsed or refractory B cell lymphoma to evaluate the
preliminary efficacy and observe PK/PD parameters of CD19-BCMA CAR - T cells immunotherapy in
patients with relapsed or refractory multiple myeloma .
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.